Published on 09/09/202509/09/2025 by Best Paper Awards Dr. Safa Tahmasebi | Biochemistry | Best Researcher Award PhD of Immunology at Shahid Beheshti University of Medical Sciences | Iran Dr. Safa Tahmasebi is an accomplished researcher in medical immunology, with expertise in cancer immunotherapy, stem cell biology, exosome research, and immune regulation in infectious and autoimmune diseases. Holding a PhD in Medical Immunology from Shahid Beheshti University of Medical Sciences, she has led and collaborated on numerous impactful projects, including translational research on CAR-T and CAR-NK therapies and novel immunotherapeutic strategies. She has authored multiple publications in high-impact journals indexed in Scopus and PubMed, alongside contributions to books and international congresses where she has delivered invited lectures and top-ranked presentations. Beyond research, she has demonstrated leadership in student research committees, organized academic workshops, and contributed to community platforms. Her achievements reflect strong academic excellence, research innovation, and a commitment to advancing global healthcare through science and education. Professional Profiles Google Scholar | Scopus | Orcid Education Dr. Safa Tahmasebi has pursued a distinguished academic path in the field of medical sciences, consistently excelling at every stage. She completed her Bachelor’s degree in Laboratory Sciences, achieving first rank throughout her studies. She then earned a Master’s in Medical Immunology, securing top positions in the national entrance examinations, followed by a PhD in Medical Immunology from Shahid Beheshti University of Medical Sciences. During her doctoral studies, she specialized in advanced immunological mechanisms, cancer immunotherapy, and translational medicine, with a strong focus on CAR-T and CAR-NK therapies. Her educational background reflects academic excellence, perseverance, and a deep commitment to scientific advancement. The rigorous training she received has laid a strong foundation for her subsequent professional and research contributions, preparing her to lead innovative projects at both national and international levels. Experience Dr. Safa Tahmasebi has gained extensive professional experience as a researcher, educator, and academic leader. She has served as an executive and collaborator in multiple high-impact research projects, including studies on immunotherapy, stem cell applications, exosomes in cancer progression, and immune responses in infectious diseases. Her role extends beyond laboratory research into teaching, where she has conducted theoretical and practical courses in immunology for students in medicine, nursing, pharmacy, and dentistry. She has also organized advanced workshops on systematic reviews, SPSS, ELISA, and cancer immunology, equipping young researchers with essential scientific skills. Additionally, she has been actively involved in student research committees and community platforms, taking leadership roles in guiding scientific initiatives. Through these experiences, she has demonstrated a balance of research innovation, academic mentoring, and community engagement. Research Interest Dr. Safa Tahmasebi’s research interests lie at the intersection of immunology, oncology, and translational medicine, with a particular focus on innovative therapeutic strategies. Her primary work involves developing and improving cancer immunotherapies such as CAR-T and CAR-NK cell therapies, investigating tumor microenvironment dynamics, and exploring the roles of exosomes and non-coding RNAs in cancer progression. She is also deeply engaged in studying immune regulation in autoimmune and infectious diseases, including COVID-19, where she has published widely on vaccine responses and immunomodulatory therapies. Her interests extend to anti-aging research, stem cell-based therapies, and the application of artificial intelligence in cancer prediction and treatment. With an emphasis on bridging laboratory research with clinical application, her vision is to advance therapies that significantly improve patient outcomes and contribute to global health solutions. Awards and Honors Dr. Safa Tahmasebi has received numerous awards and honors that recognize her academic excellence, research achievements, and community contributions. She has consistently ranked first in national examinations for both her Master’s and PhD programs, highlighting her strong academic foundation. Her achievements include being selected as a model student at both institutional and provincial levels, receiving the National Student Dedication Award for social responsibility, and earning recognition from the National Elite Foundation through multiple Shahid Zazai Projects for top students. She has also been honored as the Outstanding Research Student and selected for the Immunology and Allergy Festival as a leading PhD researcher. These accolades reflect her commitment to scientific excellence, leadership, and service to society, reinforcing her reputation as a highly accomplished and respected young researcher. Research Skills Dr. Safa Tahmasebi possesses a comprehensive set of research skills that combine technical expertise with strong analytical and leadership abilities. She is proficient in advanced laboratory techniques such as cell culture, ELISA, flow cytometry, molecular biology methods, and immunological assays. Her expertise extends to systematic reviews, meta-analysis, and the application of statistical tools like SPSS for biomedical research. She has successfully led projects involving experimental models of cancer, immunomodulatory therapies, and exosome-based studies, demonstrating skill in both experimental design and translational application. Additionally, she has significant experience in academic writing, with numerous publications in high-impact journals, books, and conference proceedings. Her ability to lead interdisciplinary projects, collaborate internationally, and mentor students underscores her strengths not only as a researcher but also as an academic leader committed to advancing medical science. Publication Top Notes Title: CAR T cells in solid tumors: challenges and opportunitiesYear: 2021Citations: 660 Title: Exosome engineering in cell therapy and drug deliveryYear: 2023Citations: 250 Title: Recent advances in non-small cell lung cancer targeted therapy; an update reviewYear: 2023Citations: 228 Title: Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patientsYear: 2021Citations: 202 Title: Th17 and Treg cells function in SARS‐CoV2 patients compared with healthy controlsYear: 2020Citations: 184 Title: The effects of oxygen–ozone therapy on regulatory T‐cell responses in multiple sclerosis patientsYear: 2021Citations: 171 Title: CAR-T cell combination therapy: the next revolution in cancer treatmentYear: 2022Citations: 135 Title: Solid tumors challenges and new insights of CAR T cell engineeringYear: 2019Citations: 122 Title: Immune cell hacking: challenges and clinical approaches to create smarter generations of chimeric antigen receptor T cellsYear: 2018Citations: 93 Title: CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapyYear: 2023Citations: 74 Title: Nanocurcumin improves Treg cell responses in patients with mild and severe SARS-CoV2Year: 2021Citations: 74 Title: Chimeric antigen receptor-T cell therapy: Applications and challenges in treatment of allergy and asthmaYear: 2020Citations: 73 Title: Programmable and multi-targeted CARs: a new breakthrough in cancer CAR-T cell therapyYear: 2020Citations: 61 Title: The outlook for diagnostic purposes of the 2019‐novel coronavirus diseaseYear: 2020Citations: 49 Title: Study of immunomodulatory effects of mesenchymal stem cell-derived exosomes in a mouse model of LPS induced systemic inflammationYear: 2022Citations: 41 Title: Pro-tumorigenic and Anti-tumorigenic Roles of Pro-inflammatory Cytokines in CancerYear: 2022Citations: 40 Title: Changes in Th17 cells frequency and function after ozone therapy used to treat multiple sclerosis patientsYear: 2020Citations: 39 Title: Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimismYear: 2021Citations: 38 Title: Mesenchymal stem cell-based therapy as a new therapeutic approach for acute inflammationYear: 2023Citations: 34 Title: Longevity and anti-aging effects of curcumin supplementationYear: 2024Citations: 33 Title: Recent advances in antibody‐based immunotherapy strategies for COVID‐19Year: 2021Citations: 33 Title: E3 ubiquitin ligase Casitas B lineage lymphoma-b and its potential therapeutic implications for immunotherapyYear: 2021Citations: 32 Title: IL-38 as an early predictor of the ischemic stroke prognosisYear: 2021Citations: 30 Title: Risk factors for adverse outcomes of COVID-19 patients: Possible basis for diverse responses to the novel coronavirus SARS-CoV-2Year: 2021Citations: 30 Title: Immune-based therapy for COVID-19Year: 2021Citations: 26 Title: Th17 cell function in cancers: immunosuppressive agents or anti-tumor allies?Year: 2024Citations: 20 Title: Immunomodulatory role of Nanocurcumin in COVID-19 patients with dropped natural killer cells frequency and functionYear: 2022Citations: 16 Title: Epigenetic biomarkers in aging and longevity: Current and future applicationYear: 2024Citations: 15 Title: Cellular and biological factors involved in healing wounds and burns and treatment options in tissue engineeringYear: 2022Citations: 15 Title: Handbook of cancer and immunologyYear: 2022Citations: 15 Title: Artificial intelligence for prediction of metastasis risk and survivalYear: 2024Citations: 11 Title: The effects of methotrexate on the immune responses to the COVID-19 vaccines in the patients with immune-mediated inflammatory diseaseYear: 2023Citations: 10 Title: CAR-modified immune cells as a rapidly evolving approach in the context of cancer immunotherapiesYear: 2023Citations: 9 Title: COVID-19: our current knowledge of epidemiology, pathology, therapeutic approaches, and diagnostic methodsYear: 2021Citations: 9 Title: Harnessing the power of exosomes for diagnosis, prognosis, and treatment of hematological malignanciesYear: 2025Citations: 7 Title: Immunogenicity of COVID‐19 vaccines in adult patients with autoimmune inflammatory rheumatic diseases: a systematic review and meta‐analysisYear: 2023Citations: 7 Title: Recent innovative approaches to intensify the efficacy and safety of CAR-T cell therapy in cancersYear: 2022Citations: 6 Title: Glycolysis and Autoimmune Diseases: A Growing RelationshipYear: 2020Citations: 6 Title: Harnessing immunotherapy for hepatocellular carcinoma: Principles and emerging promisesYear: 2025Citations: 5 Title: Effect of genetic profiling on surgical decisions at hereditary colorectal cancer syndromesYear: 2024Citations: 5 Title: The effects of guluronic acid (G2013), a new emerging treatment, on inflammatory factors in nonalcoholic steatohepatitis patients under in vitro conditionsYear: 2021Citations: 3 Title: Harnessing the fundamental roles of vitamins: the potent anti-oxidants in longevityYear: 2025Citations: 2 Title: Peptides in breast cancer therapy: From mechanisms to emerging drug delivery and immunotherapy strategiesYear: 2025Citations: 2 Title: Harnessing IL-27: challenges and potential in cancer immunotherapyYear: 2025Citations: 2 Title: Anti-aging natural supplements: the main players in promoting healthy lifespanYear: 2024Citations: 2 Title: The Assessment of Anti–SARS‐CoV‐2 Antibodies in Different Vaccine PlatformsYear: 2024Citations: 2 Title: Immunity to tetanus vaccination in pregnant women in Zanjan province, northwest of IranYear: 2018Citations: 2 Title: Applications of CRISPR-Cas9 in mitigating cellular senescence and age-related disease progressionYear: 2025Citation: 1 Title: CCAT2 role in gastrointestinal cancer progression and metastasisYear: 2025Citation: 1 Title: Breaking barriers: CAR-NK cell therapy breakthroughs in female-related cancersYear: 2025Citation: 1 Title: DCLK1 in gastrointestinal cancer: A driver of tumor progression and a promising therapeutic targetYear: 2025Citation: 1 Title: Macrophage polarization in hepatocellular carcinoma: a lncRNA-centric perspective on tumor progression and metastasisYear: 2025Citation: 1 Title: Translating preclinical insights into clinical strategies: Targeting cancer stem cells and stemness in prostate cancerYear: 2025Citation: 1 Conclusion In conclusion, Dr. Safa Tahmasebi represents an exceptional example of academic excellence, research innovation, and leadership in the field of medical immunology. With a strong educational foundation, extensive professional experience, and impactful research contributions in cancer immunotherapy, stem cell biology, and immune regulation, she has established herself as a promising scientist. Her awards and honors further demonstrate her commitment to excellence, while her diverse research skills highlight her ability to bridge theory and practice. Through her publications, lectures, and community involvement, she has already made significant contributions to science and society. With her vision for advancing immunological therapies and her ability to inspire and mentor others, she holds immense potential to continue making groundbreaking contributions and is highly deserving of recognition through prestigious research awards. Safa Tahmasebi | Biochemistry | Best Researcher Award | 10070
Dr. Safa Tahmasebi is an accomplished researcher in medical immunology, with expertise in cancer immunotherapy, stem cell biology, exosome research, and immune regulation in infectious and autoimmune diseases. Holding a PhD in Medical Immunology from Shahid Beheshti University of Medical Sciences, she has led and collaborated on numerous impactful projects, including translational research on CAR-T and CAR-NK therapies and novel immunotherapeutic strategies. She has authored multiple publications in high-impact journals indexed in Scopus and PubMed, alongside contributions to books and international congresses where she has delivered invited lectures and top-ranked presentations. Beyond research, she has demonstrated leadership in student research committees, organized academic workshops, and contributed to community platforms. Her achievements reflect strong academic excellence, research innovation, and a commitment to advancing global healthcare through science and education. Professional Profiles Google Scholar | Scopus | Orcid Education Dr. Safa Tahmasebi has pursued a distinguished academic path in the field of medical sciences, consistently excelling at every stage. She completed her Bachelor’s degree in Laboratory Sciences, achieving first rank throughout her studies. She then earned a Master’s in Medical Immunology, securing top positions in the national entrance examinations, followed by a PhD in Medical Immunology from Shahid Beheshti University of Medical Sciences. During her doctoral studies, she specialized in advanced immunological mechanisms, cancer immunotherapy, and translational medicine, with a strong focus on CAR-T and CAR-NK therapies. Her educational background reflects academic excellence, perseverance, and a deep commitment to scientific advancement. The rigorous training she received has laid a strong foundation for her subsequent professional and research contributions, preparing her to lead innovative projects at both national and international levels. Experience Dr. Safa Tahmasebi has gained extensive professional experience as a researcher, educator, and academic leader. She has served as an executive and collaborator in multiple high-impact research projects, including studies on immunotherapy, stem cell applications, exosomes in cancer progression, and immune responses in infectious diseases. Her role extends beyond laboratory research into teaching, where she has conducted theoretical and practical courses in immunology for students in medicine, nursing, pharmacy, and dentistry. She has also organized advanced workshops on systematic reviews, SPSS, ELISA, and cancer immunology, equipping young researchers with essential scientific skills. Additionally, she has been actively involved in student research committees and community platforms, taking leadership roles in guiding scientific initiatives. Through these experiences, she has demonstrated a balance of research innovation, academic mentoring, and community engagement. Research Interest Dr. Safa Tahmasebi’s research interests lie at the intersection of immunology, oncology, and translational medicine, with a particular focus on innovative therapeutic strategies. Her primary work involves developing and improving cancer immunotherapies such as CAR-T and CAR-NK cell therapies, investigating tumor microenvironment dynamics, and exploring the roles of exosomes and non-coding RNAs in cancer progression. She is also deeply engaged in studying immune regulation in autoimmune and infectious diseases, including COVID-19, where she has published widely on vaccine responses and immunomodulatory therapies. Her interests extend to anti-aging research, stem cell-based therapies, and the application of artificial intelligence in cancer prediction and treatment. With an emphasis on bridging laboratory research with clinical application, her vision is to advance therapies that significantly improve patient outcomes and contribute to global health solutions. Awards and Honors Dr. Safa Tahmasebi has received numerous awards and honors that recognize her academic excellence, research achievements, and community contributions. She has consistently ranked first in national examinations for both her Master’s and PhD programs, highlighting her strong academic foundation. Her achievements include being selected as a model student at both institutional and provincial levels, receiving the National Student Dedication Award for social responsibility, and earning recognition from the National Elite Foundation through multiple Shahid Zazai Projects for top students. She has also been honored as the Outstanding Research Student and selected for the Immunology and Allergy Festival as a leading PhD researcher. These accolades reflect her commitment to scientific excellence, leadership, and service to society, reinforcing her reputation as a highly accomplished and respected young researcher. Research Skills Dr. Safa Tahmasebi possesses a comprehensive set of research skills that combine technical expertise with strong analytical and leadership abilities. She is proficient in advanced laboratory techniques such as cell culture, ELISA, flow cytometry, molecular biology methods, and immunological assays. Her expertise extends to systematic reviews, meta-analysis, and the application of statistical tools like SPSS for biomedical research. She has successfully led projects involving experimental models of cancer, immunomodulatory therapies, and exosome-based studies, demonstrating skill in both experimental design and translational application. Additionally, she has significant experience in academic writing, with numerous publications in high-impact journals, books, and conference proceedings. Her ability to lead interdisciplinary projects, collaborate internationally, and mentor students underscores her strengths not only as a researcher but also as an academic leader committed to advancing medical science. Publication Top Notes Title: CAR T cells in solid tumors: challenges and opportunitiesYear: 2021Citations: 660 Title: Exosome engineering in cell therapy and drug deliveryYear: 2023Citations: 250 Title: Recent advances in non-small cell lung cancer targeted therapy; an update reviewYear: 2023Citations: 228 Title: Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patientsYear: 2021Citations: 202 Title: Th17 and Treg cells function in SARS‐CoV2 patients compared with healthy controlsYear: 2020Citations: 184 Title: The effects of oxygen–ozone therapy on regulatory T‐cell responses in multiple sclerosis patientsYear: 2021Citations: 171 Title: CAR-T cell combination therapy: the next revolution in cancer treatmentYear: 2022Citations: 135 Title: Solid tumors challenges and new insights of CAR T cell engineeringYear: 2019Citations: 122 Title: Immune cell hacking: challenges and clinical approaches to create smarter generations of chimeric antigen receptor T cellsYear: 2018Citations: 93 Title: CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapyYear: 2023Citations: 74 Title: Nanocurcumin improves Treg cell responses in patients with mild and severe SARS-CoV2Year: 2021Citations: 74 Title: Chimeric antigen receptor-T cell therapy: Applications and challenges in treatment of allergy and asthmaYear: 2020Citations: 73 Title: Programmable and multi-targeted CARs: a new breakthrough in cancer CAR-T cell therapyYear: 2020Citations: 61 Title: The outlook for diagnostic purposes of the 2019‐novel coronavirus diseaseYear: 2020Citations: 49 Title: Study of immunomodulatory effects of mesenchymal stem cell-derived exosomes in a mouse model of LPS induced systemic inflammationYear: 2022Citations: 41 Title: Pro-tumorigenic and Anti-tumorigenic Roles of Pro-inflammatory Cytokines in CancerYear: 2022Citations: 40 Title: Changes in Th17 cells frequency and function after ozone therapy used to treat multiple sclerosis patientsYear: 2020Citations: 39 Title: Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimismYear: 2021Citations: 38 Title: Mesenchymal stem cell-based therapy as a new therapeutic approach for acute inflammationYear: 2023Citations: 34 Title: Longevity and anti-aging effects of curcumin supplementationYear: 2024Citations: 33 Title: Recent advances in antibody‐based immunotherapy strategies for COVID‐19Year: 2021Citations: 33 Title: E3 ubiquitin ligase Casitas B lineage lymphoma-b and its potential therapeutic implications for immunotherapyYear: 2021Citations: 32 Title: IL-38 as an early predictor of the ischemic stroke prognosisYear: 2021Citations: 30 Title: Risk factors for adverse outcomes of COVID-19 patients: Possible basis for diverse responses to the novel coronavirus SARS-CoV-2Year: 2021Citations: 30 Title: Immune-based therapy for COVID-19Year: 2021Citations: 26 Title: Th17 cell function in cancers: immunosuppressive agents or anti-tumor allies?Year: 2024Citations: 20 Title: Immunomodulatory role of Nanocurcumin in COVID-19 patients with dropped natural killer cells frequency and functionYear: 2022Citations: 16 Title: Epigenetic biomarkers in aging and longevity: Current and future applicationYear: 2024Citations: 15 Title: Cellular and biological factors involved in healing wounds and burns and treatment options in tissue engineeringYear: 2022Citations: 15 Title: Handbook of cancer and immunologyYear: 2022Citations: 15 Title: Artificial intelligence for prediction of metastasis risk and survivalYear: 2024Citations: 11 Title: The effects of methotrexate on the immune responses to the COVID-19 vaccines in the patients with immune-mediated inflammatory diseaseYear: 2023Citations: 10 Title: CAR-modified immune cells as a rapidly evolving approach in the context of cancer immunotherapiesYear: 2023Citations: 9 Title: COVID-19: our current knowledge of epidemiology, pathology, therapeutic approaches, and diagnostic methodsYear: 2021Citations: 9 Title: Harnessing the power of exosomes for diagnosis, prognosis, and treatment of hematological malignanciesYear: 2025Citations: 7 Title: Immunogenicity of COVID‐19 vaccines in adult patients with autoimmune inflammatory rheumatic diseases: a systematic review and meta‐analysisYear: 2023Citations: 7 Title: Recent innovative approaches to intensify the efficacy and safety of CAR-T cell therapy in cancersYear: 2022Citations: 6 Title: Glycolysis and Autoimmune Diseases: A Growing RelationshipYear: 2020Citations: 6 Title: Harnessing immunotherapy for hepatocellular carcinoma: Principles and emerging promisesYear: 2025Citations: 5 Title: Effect of genetic profiling on surgical decisions at hereditary colorectal cancer syndromesYear: 2024Citations: 5 Title: The effects of guluronic acid (G2013), a new emerging treatment, on inflammatory factors in nonalcoholic steatohepatitis patients under in vitro conditionsYear: 2021Citations: 3 Title: Harnessing the fundamental roles of vitamins: the potent anti-oxidants in longevityYear: 2025Citations: 2 Title: Peptides in breast cancer therapy: From mechanisms to emerging drug delivery and immunotherapy strategiesYear: 2025Citations: 2 Title: Harnessing IL-27: challenges and potential in cancer immunotherapyYear: 2025Citations: 2 Title: Anti-aging natural supplements: the main players in promoting healthy lifespanYear: 2024Citations: 2 Title: The Assessment of Anti–SARS‐CoV‐2 Antibodies in Different Vaccine PlatformsYear: 2024Citations: 2 Title: Immunity to tetanus vaccination in pregnant women in Zanjan province, northwest of IranYear: 2018Citations: 2 Title: Applications of CRISPR-Cas9 in mitigating cellular senescence and age-related disease progressionYear: 2025Citation: 1 Title: CCAT2 role in gastrointestinal cancer progression and metastasisYear: 2025Citation: 1 Title: Breaking barriers: CAR-NK cell therapy breakthroughs in female-related cancersYear: 2025Citation: 1 Title: DCLK1 in gastrointestinal cancer: A driver of tumor progression and a promising therapeutic targetYear: 2025Citation: 1 Title: Macrophage polarization in hepatocellular carcinoma: a lncRNA-centric perspective on tumor progression and metastasisYear: 2025Citation: 1 Title: Translating preclinical insights into clinical strategies: Targeting cancer stem cells and stemness in prostate cancerYear: 2025Citation: 1 Conclusion In conclusion, Dr. Safa Tahmasebi represents an exceptional example of academic excellence, research innovation, and leadership in the field of medical immunology. With a strong educational foundation, extensive professional experience, and impactful research contributions in cancer immunotherapy, stem cell biology, and immune regulation, she has established herself as a promising scientist. Her awards and honors further demonstrate her commitment to excellence, while her diverse research skills highlight her ability to bridge theory and practice. Through her publications, lectures, and community involvement, she has already made significant contributions to science and society. With her vision for advancing immunological therapies and her ability to inspire and mentor others, she holds immense potential to continue making groundbreaking contributions and is highly deserving of recognition through prestigious research awards.